Annovis Bio Q2 loss widens as R&D costs rise

Annovis Bio

14/08/2026 13:15

Overview
US biotech firm's Q2 net loss per share widened yr/yr
Company fully enrolled pivotal Phase 3 Alzheimer's trial, exceeding original target
Q2 research and development expenses more than doubled from a year earlier

Outlook
Company expects top-line symptomatic data from Phase 3 Alzheimer's trial in Q1 2027
Alzheimer's open-label extension study expected to initiate in October 2026
Full enrollment for Parkinson's disease OLE study projected in Q4 2026

Result Drivers
TRIAL ENROLLMENT - Co fully enrolled pivotal Phase 3 Alzheimer's trial with 850 patients, exceeding original target
HIGHER R&D SPENDING - Research and development expenses more than doubled yr/yr as company advanced clinical programs

Company press release: ID:nGNX3tdVSq

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.40
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Annovis Bio Inc is $10.00, about 458.7% above its August 13 closing price of $1.79

Reuters Recommended Reads
Aug 14 - US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
Aug 13 - ProMIS Neurosciences Q2 net loss widens
Aug 13 - CorMedix beats Q2 revenue estimates on DefenCath growth, raises FY adjusted EBITDA guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)